224 related articles for article (PubMed ID: 21729667)
1. Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer.
Gucalp A; Sparano JA; Caravelli J; Santamauro J; Patil S; Abbruzzi A; Pellegrino C; Bromberg J; Dang C; Theodoulou M; Massague J; Norton L; Hudis C; Traina TA
Clin Breast Cancer; 2011 Oct; 11(5):306-11. PubMed ID: 21729667
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621.
Molina JR; Foster NR; Reungwetwattana T; Nelson GD; Grainger AV; Steen PD; Stella PJ; Marks R; Wright J; Adjei AA
Lung Cancer; 2014 Aug; 85(2):245-50. PubMed ID: 24957683
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.
Reddy SM; Kopetz S; Morris J; Parikh N; Qiao W; Overman MJ; Fogelman D; Shureiqi I; Jacobs C; Malik Z; Jimenez CA; Wolff RA; Abbruzzese JL; Gallick G; Eng C
Invest New Drugs; 2015 Aug; 33(4):977-84. PubMed ID: 26062928
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.
Mackay HJ; Au HJ; McWhirter E; Alcindor T; Jarvi A; MacAlpine K; Wang L; Wright JJ; Oza AM
Invest New Drugs; 2012 Jun; 30(3):1158-63. PubMed ID: 21400081
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies.
Gubens MA; Burns M; Perkins SM; Pedro-Salcedo MS; Althouse SK; Loehrer PJ; Wakelee HA
Lung Cancer; 2015 Jul; 89(1):57-60. PubMed ID: 26009269
[TBL] [Abstract][Full Text] [Related]
6. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
Baselga J; Cervantes A; Martinelli E; Chirivella I; Hoekman K; Hurwitz HI; Jodrell DI; Hamberg P; Casado E; Elvin P; Swaisland A; Iacona R; Tabernero J
Clin Cancer Res; 2010 Oct; 16(19):4876-83. PubMed ID: 20805299
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
Lara PN; Longmate J; Evans CP; Quinn DI; Twardowski P; Chatta G; Posadas E; Stadler W; Gandara DR
Anticancer Drugs; 2009 Mar; 20(3):179-84. PubMed ID: 19396016
[TBL] [Abstract][Full Text] [Related]
8. First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours.
Fujisaka Y; Onozawa Y; Kurata T; Yasui H; Goto I; Yamazaki K; Machida N; Watanabe J; Shimada H; Shi X; Boku N
Invest New Drugs; 2013 Feb; 31(1):108-14. PubMed ID: 22415795
[TBL] [Abstract][Full Text] [Related]
9. Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer.
Arcaroli J; Quackenbush K; Dasari A; Powell R; McManus M; Tan AC; Foster NR; Picus J; Wright J; Nallapareddy S; Erlichman C; Hidalgo M; Messersmith WA
Cancer Med; 2012 Oct; 1(2):207-17. PubMed ID: 23342270
[TBL] [Abstract][Full Text] [Related]
10. Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study.
Hannon RA; Finkelman RD; Clack G; Iacona RB; Rimmer M; Gossiel F; Baselga J; Eastell R
Bone; 2012 Apr; 50(4):885-92. PubMed ID: 22245630
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.
Gangadhar TC; Clark JI; Karrison T; Gajewski TF
Invest New Drugs; 2013 Jun; 31(3):769-73. PubMed ID: 23151808
[TBL] [Abstract][Full Text] [Related]
12. Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study.
Posadas EM; Ahmed RS; Karrison T; Szmulewitz RZ; O'Donnell PH; Wade JL; Shen J; Gururajan M; Sievert M; Stadler WM
Prostate; 2016 Feb; 76(3):286-93. PubMed ID: 26493492
[TBL] [Abstract][Full Text] [Related]
13. A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer.
Renouf DJ; Moore MJ; Hedley D; Gill S; Jonker D; Chen E; Walde D; Goel R; Southwood B; Gauthier I; Walsh W; McIntosh L; Seymour L
Invest New Drugs; 2012 Apr; 30(2):779-86. PubMed ID: 21170669
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial.
Park YH; Lee KH; Sohn JH; Lee KS; Jung KH; Kim JH; Lee KH; Ahn JS; Kim TY; Kim GM; Park IH; Kim SB; Kim SH; Han HS; Im YH; Ahn JH; Kim JY; Kang J; Im SA
Int J Cancer; 2018 Dec; 143(12):3240-3247. PubMed ID: 29978467
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium.
Laurie SA; Goss GD; Shepherd FA; Reaume MN; Nicholas G; Philip L; Wang L; Schwock J; Hirsh V; Oza A; Tsao MS; Wright JJ; Leighl NB
Clin Lung Cancer; 2014 Jan; 15(1):52-7. PubMed ID: 24169259
[TBL] [Abstract][Full Text] [Related]
16. Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial.
Thallinger C; Lang I; Kuhar CG; Bartsch R; Singer CF; Petruzelka L; Melichar B; Knittelfelder R; Brodowicz T; Zielinski C
BMC Cancer; 2016 Feb; 16():121. PubMed ID: 26887956
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Fury MG; Baxi S; Shen R; Kelly KW; Lipson BL; Carlson D; Stambuk H; Haque S; Pfister DG
Anticancer Res; 2011 Jan; 31(1):249-53. PubMed ID: 21273606
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
Gucalp A; Tolaney S; Isakoff SJ; Ingle JN; Liu MC; Carey LA; Blackwell K; Rugo H; Nabell L; Forero A; Stearns V; Doane AS; Danso M; Moynahan ME; Momen LF; Gonzalez JM; Akhtar A; Giri DD; Patil S; Feigin KN; Hudis CA; Traina TA;
Clin Cancer Res; 2013 Oct; 19(19):5505-12. PubMed ID: 23965901
[TBL] [Abstract][Full Text] [Related]
19. Effects of the Src inhibitor saracatinib (AZD0530) on renal function in healthy subjects.
Dalton RN; Chetty R; Stuart M; Iacona RB; Swaisland A
Anticancer Res; 2010 Jul; 30(7):2935-42. PubMed ID: 20683035
[TBL] [Abstract][Full Text] [Related]
20. A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†.
McNeish IA; Ledermann JA; Webber L; James L; Kaye SB; Hall M; Hall G; Clamp A; Earl H; Banerjee S; Kristeleit R; Raja F; Feeney A; Lawrence C; Dawson-Athey L; Persic M; Khan I
Ann Oncol; 2014 Oct; 25(10):1988-1995. PubMed ID: 25070546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
